The Record
← House Dashboard
HR-8205 119th Congress

Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026

Passed Senate without amendment by Voice Vote. (consideration: CR S5120)

  1. Introduced
  2. Committee
  3. House
  4. Senate
  5. President
  6. Law

Official Summary

Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026 This bill reauthorizes through FY2031 and revises programs that support research and development of drugs and other therapies to address amyotrophic lateral sclerosis (also known as ALS or Lou Gehrig's disease) and other neurodegenerative diseases. The bill reauthorizes grants from the National Institutes of Health (NIH) for scientific research on investigational drugs to prevent or treat ALS for individuals not otherwise eligible for clinical trials, grants from the Food and Drug Administration (FDA) for research and development of therapies to prevent and treat ALS and other neurodegenerative diseases, and a Public-Private Partnership including the FDA and NIH that supports development and regulatory review of treatments for neurodegenerative diseases. Also, the NIH, in considering renewal of its grants, must assess available information on the safety and efficacy of the investigational drugs. It must also require grantees to promptly report serious and unexpected adverse events associated with their investigational drugs. Additionally, the FDA must publish a plan describing actions it will take over a five-year period to foster development of safe and effective drugs, and facilitate access to investigational drugs, that treat ALS and other rare neurodegenerative diseases. The FDA must also publish a report describing the actions it has taken under the plan.

Actions

  1. Sep 28, 2026 · Senate
    Passed Senate without amendment by Voice Vote. (consideration: CR S5120)
  2. Sep 28, 2026 · House
    Passed/agreed to in Senate: Passed Senate without amendment by Voice Vote. (consideration: CR S5120)
  3. Jul 23, 2026 · Senate
    Received in the Senate. Read twice. Placed on Senate Legislative Calendar under General Orders. Calendar No. 466.
  4. Jul 22, 2026 · House
    Motion to reconsider laid on the table Agreed to without objection.
  5. Jul 22, 2026 · House
    On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote.
  6. Jul 22, 2026 · House
    Passed/agreed to in House: On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote.
  7. Jul 22, 2026 · House
    Considered as unfinished business. (consideration: CR H5159)
  8. Jul 20, 2026 · House
    At the conclusion of debate, the chair put the question on the motion to suspend the rules. Mr. Guthrie objected to the vote on the grounds that a quorum was not present. Further proceedings on the motion were postponed. The point of no quorum was considered as withdrawn.
  9. Jul 20, 2026 · House
    DEBATE - The House proceeded with forty minutes of debate on H.R. 8205.
  10. Jul 20, 2026 · House
    Considered under suspension of the rules. (consideration: CR H4652-4654; text: CR H4653)
  11. Jul 20, 2026 · House
    Mr. Guthrie moved to suspend the rules and pass the bill, as amended.
  12. Jul 9, 2026 · House
    Placed on the Union Calendar, Calendar No. 637.
  13. Jul 9, 2026 · House
    Reported (Amended) by the Committee on Energy and Commerce. H. Rept. 119-733.
  14. Jul 9, 2026 · House
    Reported (Amended) by the Committee on Energy and Commerce. H. Rept. 119-733.
  15. May 21, 2026 · House
    Ordered to be Reported (Amended) by the Yeas and Nays: 46 - 0.
  16. May 21, 2026 · House
    Committee Consideration and Mark-up Session Held
  17. May 13, 2026 · House
    Forwarded by Subcommittee to Full Committee by Voice Vote.
  18. May 13, 2026 · House
    Subcommittee Consideration and Mark-up Session Held
  19. Apr 6, 2026 · House
    Referred to the Subcommittee on Health.
  20. Apr 6, 2026 · House
    Referred to the House Committee on Energy and Commerce.
  21. Apr 6, 2026 · House
    Introduced in House
  22. Apr 6, 2026 · House
    Introduced in House

Full Text & Official Record

Full bill text, amendments, and the complete action history are maintained by Congress.gov, the authoritative public record.

View on Congress.gov →